Highland Capital Management LLC Sells 1,100 Shares of Fresenius Medical Care AG (NYSE:FMS)

Highland Capital Management LLC trimmed its stake in shares of Fresenius Medical Care AG (NYSE:FMS) by 2.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 43,100 shares of the company’s stock after selling 1,100 shares during the quarter. Highland Capital Management LLC’s holdings in Fresenius Medical Care were worth $976,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Moran Wealth Management LLC raised its stake in Fresenius Medical Care by 47.0% in the third quarter. Moran Wealth Management LLC now owns 233,376 shares of the company’s stock valued at $4,971,000 after purchasing an additional 74,621 shares in the last quarter. Quantinno Capital Management LP increased its holdings in Fresenius Medical Care by 78.9% in the 3rd quarter. Quantinno Capital Management LP now owns 110,078 shares of the company’s stock valued at $2,345,000 after buying an additional 48,554 shares during the period. Crossmark Global Holdings Inc. raised its position in shares of Fresenius Medical Care by 60.4% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 62,889 shares of the company’s stock valued at $1,340,000 after buying an additional 23,692 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Fresenius Medical Care during the 3rd quarter worth approximately $420,000. Finally, XTX Topco Ltd boosted its position in shares of Fresenius Medical Care by 70.8% during the 3rd quarter. XTX Topco Ltd now owns 39,769 shares of the company’s stock worth $847,000 after acquiring an additional 16,487 shares in the last quarter. 8.37% of the stock is owned by institutional investors and hedge funds.

Fresenius Medical Care Stock Up 0.4 %

Shares of NYSE:FMS opened at $24.95 on Friday. Fresenius Medical Care AG has a 52-week low of $17.93 and a 52-week high of $25.17. The company has a market capitalization of $14.64 billion, a PE ratio of 20.62, a price-to-earnings-growth ratio of 0.75 and a beta of 0.92. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. The company has a fifty day moving average of $23.09 and a 200-day moving average of $21.15.

Fresenius Medical Care (NYSE:FMS) last issued its earnings results on Tuesday, November 5th. The company reported $0.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.42 by $0.03. Fresenius Medical Care had a return on equity of 6.04% and a net margin of 3.43%. The business had revenue of $5.23 billion during the quarter, compared to analysts’ expectations of $5.36 billion. During the same quarter in the prior year, the firm earned $0.31 EPS. On average, equities analysts predict that Fresenius Medical Care AG will post 1.53 EPS for the current fiscal year.

Analyst Ratings Changes

FMS has been the subject of several research analyst reports. Bank of America upgraded shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd. Truist Financial boosted their price target on Fresenius Medical Care from $23.00 to $25.00 and gave the stock a “hold” rating in a report on Monday, January 6th. StockNews.com began coverage on Fresenius Medical Care in a research note on Friday, January 3rd. They issued a “strong-buy” rating on the stock. Finally, Berenberg Bank began coverage on Fresenius Medical Care in a research note on Wednesday, November 6th. They set a “buy” rating and a $25.60 target price for the company.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.